Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis

Haemophilia

Volumn 17, Issue 6, 2011, Pages 944-951

  Veyradier, A ^a,b,c   Caron, C ^c,d   Ternisien, C ^c,e   Wolf, M ^a,b,c   Trossaert, M ^c,e   Fressinaud, E ^a,b,c   Goudemand, J ^c,d  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Centre National de Référence de la Maladie de Willebrand   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔTEL DIEU   (France)

Author keywords

ELISA; Haemophilia A; Von Willebrand factor to factor VIII binding assay; Von Willebrand's disease type 2N

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; PEROXIDASE; POLYCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HEMOPHILIA A; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TYPE 2N VON WILLEBRAND DISEASE; VALIDATION STUDY; VON WILLEBRAND DISEASE; ANALYTICAL EQUIPMENT; GENETICS; METABOLISM; METHODOLOGY; MUTATION; REPRODUCIBILITY;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HUMANS; MUTATION; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASE, TYPE 2; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84857925437     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02499.x     Document Type: Article

References (25)

1. Meyer D, Fressinaud E, Mazurier C. Clinical, laboratory and molecular markers of type 2 von Willebrand disease. In: Federici AB, Berntop E, Lillicrap D, Montgomery R eds. Von Willebrand Disease: Basic and Clinical Aspects, 1st edn. Oxford: Blackwell publishing, 2010: 137-47.
2. Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
3. Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Educ Program 2009; 106-12. Review.
4. Nichols WL, Rick ME, Ortel TL et al. Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. Am J Hematol 2009; 84: 366-70.
5. Sadler JE. Von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 3: 1702-9.
6. Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
7. Fressinaud E, Mazurier C, Meyer D. Molecular genetics of type 2 von Willebrand disease. Int J Hematol 2002; 75: 9-18.
8. Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-9.
9. Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20-6.
10. Gaucher C, Jorieux S, Mercier B, Oufkir D, Mazurier C. The "Normandy" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. Blood 1991; 77: 1937-41.
11. Lopez-Fernandez MF, Blanco-Lopez MJ, Castineira MP, Batlle J. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII. Am J Hematol 1992; 40: 20-7.
12. Eikenboom JC, Reitsma PH, Peerlinck KM, Briet E. Recessive inheritance of von Willebrand's disease type I. Lancet 1993; 341: 982-6.
13. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14: 337-47.
14. Available at University of Sheffield, UK. Accessed October 3, 2010.
15. Mazurier C, Meyer D. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease - results of an international survey. On behalf of the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1996; 76: 270-4.
16. Bowen DJ, Standen GR, Mazurier C et al. Type 2N von Willebrand disease: rapid genetic diagnosis of G2811A (R854Q), C2696T (R816W), T2701A (H817Q) and G2823T (C858F) detection of a novel candidate type 2N mutation: C2810T (R854W). Thromb Haemost 1998; 80: 32-6.
17. Schneppenheim R, Budde U, Krey S et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type I. Thromb Haemost 1996; 76: 598-602.
18. Mazurier C. Something new about type Normandy von Willebrand disease (type 2N VWD)? Thromb Haemost 2004; 92: 1-2.
19. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A, Goudemand M. Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed as heamophilia A carriers: consequences for therapy and genetic counselling. Br J Haematol 1990; 76: 372-9.
20. Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A. The evaluation of factor VIII binding activity of VWF by means of an ELISA method: significance and practical application. Am J Clin Pathol 1998; 109: 347-52.
21. Miller CH, Kelley L, Green D. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor. Am J Hematol 1998; 58: 311-8.
22. Taylor SL, Bromidge E, Savidge GF, Alhaq A. Evaluation of an automated screening assay for von Willebrand disease type 2N. Clin Lab Haematol 2002; 24: 369-75.
23. Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol 2002; 117: 716-8.
24. Zhukov O, Popov J, Ramos R et al. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory. Haemophilia 2009; 15: 788-96.
25. Casonato A, Pontara E, Sartorello F et al. Identifying carriers of type 2N von Willebrand disease: procedures and significance. Clin Appl Thromb Haemost 2007; 13: 194-200.